Back to Resources
Reference Chart

ASO Chemistry Comparison Chart

Complete reference for backbone modifications, sugar chemistries, ASO architectures, and mechanism matching — all in one place.

Backbone Modifications

Phosphodiester (PO)

Natural DNA/RNA

Advantages

Natural backbone
No stereoisomers

Considerations

Rapidly degraded by nucleases
Not suitable for therapeutics

FDA examples: Research reagents only

Phosphorothioate (PS)

Sulfur replaces non-bridging oxygen

Advantages

Nuclease resistant
Binds plasma proteins
Enables tissue distribution
Long half-life

Considerations

Injection site reactions
Complement activation at high doses
Platelet effects
Creates stereoisomers (Rp/Sp)

FDA examples: Nusinersen, Inotersen, Mipomersen

Morpholino (PMO)

Morpholine ring + neutral backbone

Advantages

Excellent safety profile
No protein binding
Water soluble

Considerations

Poor cellular uptake without conjugation
Kidney accumulation
Higher manufacturing cost

FDA examples: Eteplirsen, Golodirsen, Casimersen

Sugar Modifications (2' Position)

Modifications at the 2' position increase binding affinity and nuclease resistance. 2'-modified nucleotides are not compatible with RNase H — used in wings only for gapmers.

ModificationFull NameTm BoostRNase HNuclease ResistanceNotes
2'-H (DNA)DeoxyriboseBaseline✓ YesLowUsed in gapmer central region
2'-OMe2'-O-Methyl+1°C/nt✗ NoModerateCost-effective; moderate affinity
2'-MOE2'-O-Methoxyethyl+1-2°C/nt✗ NoHighGold standard; FDA-validated
2'-F2'-Fluoro+1.5°C/nt✗ NoHighOften combined with 2'-OMe
LNALocked Nucleic Acid+3-6°C/nt✗ NoVery HighHighest affinity; hepatotoxicity risk
cEtConstrained Ethyl+3-5°C/nt✗ NoVery HighImproved safety vs LNA

ASO Architectures

Gapmer

RNase H-Mediated Knockdown
MOE
MOE
MOE
MOE
MOE
DNA
DNA
DNA
DNA
DNA
DNA
DNA
DNA
DNA
DNA
MOE
MOE
MOE
MOE
MOE

Modified wings protect from degradation and increase affinity. The central DNA gap recruits RNase H to cleave the target RNA.

Typical design: 5-10-5 or 3-10-3 (wing-gap-wing)

FDA examples: Inotersen (TTR), Mipomersen (ApoB), Tofersen (SOD1)

Mixmer

Steric Blocking (Splice Modulation)
LNA
DNA
LNA
DNA
LNA
DNA
LNA
DNA
LNA
DNA
LNA
DNA
LNA
DNA
LNA

Alternating pattern prevents RNase H recruitment. Works by steric hindrance — physically blocking cellular machinery.

Typical design: Alternating modified/unmodified

FDA examples: Nusinersen (SMN2 splice switch)

Fully Modified (Uniform)

Steric Blocking with Maximum Stability
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE
MOE

Maximum nuclease resistance. Purely steric mechanism. Often used with PS backbone.

Typical design: All positions carry the same 2' modification

FDA examples: Splice modulation, miRNA inhibition

Mechanism → Chemistry Matching

Quick reference for choosing the right architecture and chemistry based on your therapeutic goal.

Therapeutic GoalArchitectureBackboneWings / SugarGap
mRNA KnockdownGapmerPS2'-MOE o cEtDNA
Exon SkippingMixmer o UniformPS o PMOLNA/MOE mixNone
Exon InclusionMixmer o UniformPS2'-MOENone
Translation BlockUniform o MixmerPS2'-MOENone
miRNA InhibitionUniform (anti-miR)PSLNANone

FDA-Approved ASO Drugs

DrugTargetMechanismChemistryRouteYear
Nusinersen (Spinraza)SMN2Splice inclusion2'-MOE PS uniformIT2016
Eteplirsen (Exondys 51)DMD exon 51Exon skippingPMOIV2016
Inotersen (Tegsedi)TTRRNase H knockdown2'-MOE PS gapmerSC2018
Golodirsen (Vyondys 53)DMD exon 53Exon skippingPMOIV2019
Casimersen (Amondys 45)DMD exon 45Exon skippingPMOIV2021
Tofersen (Qalsody)SOD1RNase H knockdown2'-MOE PS gapmerIT2023

Decision Tree: Choosing the Right Chemistry

1

Reduce target mRNA/protein levels?

Use GAPMER (MOE-DNA-MOE or cEt-DNA-cEt with PS backbone)

2

Modulate splicing (skip or include exon)?

CNS target → 2'-MOE PS uniform (Nusinersen-like) · Muscle target → PMO (Eteplirsen-like)

3

Block translation without degradation?

Use UNIFORM 2'-MOE or MIXMER design

4

Inhibit microRNA?

Use ANTI-MIR design (LNA-containing, short)

References

1. Crooke ST et al. (2021) Nat Rev Drug Discov 20:427-453. PMID: 33762737

2. Khvorova A, Watts JK. (2017) Nat Biotechnol 35:238-248. PMID: 28244990

3. Shen X, Bhattacharya D. (2019) Nucleic Acid Ther 29:141-152. PMID: 31329511

4. Hagedorn PH et al. (2018) Drug Discov Today 23:101-114. PMID: 28890197

Need Help Choosing Chemistry?

Chemistry selection requires balancing affinity, safety, mechanism, delivery, and cost. We can help.